Quanterix Corporation (QTRX) Expands Alzheimer's Test Distribution in New Jersey
Quanterix (QTRX) signed an exclusive deal with Sherman Abrams Laboratory to distribute its LucentAD Complete Alzheimer's blood test in Metro New York and New Jersey. Financial details were not disclosed.
How this was made

The 30-second read
Why it matters
The agreement expands geographic reach but offers no immediate financial impact.
Market read
A modest corporate partnership with limited immediate trading relevance.
What to watch
Potential regulatory or reimbursement hurdles could limit test adoption.
Background
Quanterix provides ultra-sensitive protein detection platforms; its Alzheimer's test is a novel blood-based diagnostic.
Ticker impact
Quanterix announced an exclusive distribution agreement for its Alzheimer's blood test in New Jersey and New York.
possible slight upside as investors price early adoption potential
No financial terms disclosed; impact depends on future test uptake.
Market effects
May signal growing interest in Alzheimer's diagnostics within the biotech sector.
Limited to New Jersey/New York healthcare market.
Minimal; no broader macro effect.
Counterpoint
Without disclosed volumes, the deal may not translate into meaningful revenue.
Key entities
- CompanyQuanterix Corporation
Developer of the Alzheimer's blood test.
- CompanySherman Abrams Laboratory
Exclusive distributor for the test in the region.

